Patents by Inventor Hassan A. Rudayni

Hassan A. Rudayni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12257315
    Abstract: A method of cytotoxically treating cancer with aluminum silicate nanorods (SNRs) including aluminum, iron, magnesium, oxygen, potassium, and oxygen comprises contacting the SNRs at a concentration of 0.5 to 2 ?g/mL with a cancerous sample. The aluminum silicate nanorods have a longest dimension of 100 nanometers (nm) to 5500 nm and a diameter of 20 nm to 250 nm. The SNRs are porous with a pore size of 1 nm to 12 nm and include cisplatin in an amount of 20 to 300 mg/g. The cancerous sample has a reduced cell viability after the contacting.
    Type: Grant
    Filed: November 18, 2024
    Date of Patent: March 25, 2025
    Assignee: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
    Inventors: Hassan A. Rudayni, Ahmed Aly Allam, Aya FadlAllah Abdelmonem Mohamed, Mostafa R. Abukhadra, Nohan Nasser Abdelfattah Ahmed
  • Patent number: 12239741
    Abstract: A drug delivery system including a nanocomposite. The nanocomposite includes a zinc phosphate core, a hydroxyapatite shell, and chitosan. The hydroxyapatite shell at least partially encloses the zinc phosphate core. Further, the chitosan at least partially wraps around the hydroxyapatite shell. The chitosan interacts with the hydroxyapatite shell through hydrogen bonding, and the nanocomposite is loaded with oxaliplatin to form the drug delivery system.
    Type: Grant
    Filed: October 15, 2024
    Date of Patent: March 4, 2025
    Assignee: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
    Inventors: Ahmed A Allam, Hassan A. Rudayni, Mostafa R. Abukhadra, Islam R. Sayed
  • Patent number: 12171841
    Abstract: A method of cytotoxically treating cancer with aluminum silicate nanorods (SNRs) including aluminum, iron, magnesium, oxygen, potassium, and oxygen comprises contacting the SNRs at a concentration of 0.5 to 2 ?g/mL with a cancerous sample. The aluminum silicate nanorods have a longest dimension of 100 nanometers (nm) to 5500 nm and a diameter of 20 nm to 250 nm. The SNRs are porous with a pore size of 1 nm to 12 nm and include cisplatin in an amount of 20 to 300 mg/g. The cancerous sample has a reduced cell viability after the contacting.
    Type: Grant
    Filed: July 19, 2024
    Date of Patent: December 24, 2024
    Assignee: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
    Inventors: Hassan A. Rudayni, Ahmed Aly Allam, Aya Fadlallah Abdelmonem Mohamed, Mostafa R. Abukhadra, Nohan Nasser Abdelfattah Ahmed
  • Patent number: 12151027
    Abstract: A drug delivery system including a nanocomposite. The nanocomposite includes a zinc phosphate core, a hydroxyapatite shell, and chitosan. The hydroxyapatite shell at least partially encloses the zinc phosphate core. Further, the chitosan at least partially wraps around the hydroxyapatite shell. The chitosan interacts with the hydroxyapatite shell through hydrogen bonding, and the nanocomposite is loaded with oxaliplatin to form the drug delivery system.
    Type: Grant
    Filed: April 19, 2024
    Date of Patent: November 26, 2024
    Assignee: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
    Inventors: Ahmed A Allam, Hassan A. Rudayni, Mostafa R. Abukhadra, Islam R. Sayed